Literature DB >> 29183639

Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer.

Stefano Crippa1, Roberto Cirocchi2, Patrick Maisonneuve3, Stefano Partelli1, Ilaria Pergolini4, Domenico Tamburrino1, Francesca Aleotti1, Michele Reni5, Massimo Falconi6.   

Abstract

BACKGROUND: Identification of factors associated with dismal survival after surgery in resectable pancreatic ductal adenocarcinoma is important to select patients for neoadjuvant treatment. The present meta-analysis aimed to compare the results of distal pancreatectomy for resectable adenocarcinoma of the pancreatic body-tail with and without splenic vessels infiltration.
METHODS: A systematic search was performed of PubMed, Embase and the Cochrane Library in accordance with PRISMA guidelines. The inclusion criteria were studies including patients who underwent distal pancreatectomy for pancreatic cancer with or without splenic vessels infiltration. 5-year overall survival (OS) was the primary outcomes. Meta-analysis was carried out applying time-to-event method.
RESULTS: Six articles with 423 patients were analysed. Patients with pathological splenic artery invasion had a worse survival compared with those without infiltration (Hazard ratio 1.76, 95% CI 1.36-2.28; P < 0.0001). A similar results was found when considering pathological splenic vessels infiltration, showing that survival was significantly poorer when splenic vein infiltration was present (Hazard ratio 1.51, 95% CI 1.19-1.93; P = 0.0009).
CONCLUSIONS: This meta-analysis showed worse survival for patients with splenic vessels infiltration undergoing distal pancreatectomy for pancreatic cancer. Splenic vessels infiltration represents the stigmata of a more aggressive disease, although resectable.
Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Pancreatic cancer; Recurrence; Splenic artery; Splenic vein; Surgery; Survival

Mesh:

Year:  2017        PMID: 29183639     DOI: 10.1016/j.ejso.2017.10.217

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

1.  Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail.

Authors:  Kei Kitamura; Minoru Esaki; Miyuki Sone; Shunsuke Sugawara; Nobuyoshi Hiraoka; Satoshi Nara; Daisuke Ban; Takeshi Takamoto; Takahiro Mizui; Kazuaki Shimada
Journal:  Ann Surg Oncol       Date:  2022-06-12       Impact factor: 4.339

2.  Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.

Authors:  Sanne Lof; Maarten Korrel; Jony van Hilst; Adnan Alseidi; Gianpaolo Balzano; Ugo Boggi; Giovanni Butturini; Riccardo Casadei; Safi Dokmak; Bjørn Edwin; Massimo Falconi; Tobias Keck; Giuseppe Malleo; Matteo de Pastena; Ales Tomazic; Hanneke Wilmink; Alessandro Zerbi; Marc G Besselink; Mohammed Abu Hilal
Journal:  Ann Surg Oncol       Date:  2019-12-17       Impact factor: 5.344

3.  Splenic-vasculature involvement is associated with poor prognosis in resected distal pancreatic cancer.

Authors:  Feng Yin; Mohammed Saad; Jingmei Lin; Christopher R Jackson; Bing Ren; Cynthia Lawson; Dipti M Karamchandani; Belen Quereda Bernabeu; Wei Jiang; Teena Dhir; Richard Zheng; Christopher W Schultz; Dongwei Zhang; Courtney L Thomas; Xuchen Zhang; Jinping Lai; Michael Schild; Xuefeng Zhang; Hao Xie; Xiuli Liu
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-11-24

4.  Prognostic impact of splenic vessel involvement and tumor size in distal pancreatectomy for adenocarcinoma: a retrospective multicentric cohort study.

Authors:  Dominique Gantois; Théophile Guilbaud; Ugo Scemama; Edouard Girard; Olivier Picaud; Marine Lefevre; Myriam Elgani; Zeinab Hamidou; Vincent Moutardier; Paul Balandraud; Mircea Chirica; Louise Barbier; David Fuks; David Jérémie Birnbaum
Journal:  Langenbecks Arch Surg       Date:  2021-08-10       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.